Table 1 Clinico-pathologic characteristics of patients with four major KRAS mutated tumors by KRAS mutation subtype.

From: Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

CRC (N = 23,797 KRAS mutated cases)

 

KRAS G12C

KRAS G12D

KRAS G12V

KRAS G13D

KRAS WT

KRAS non-G12C

G12C vs non-G12C

G12C vs. WT

# cases

1739

7312

5026

3963

24,640

22,058

–

–

Median age (range)

60 (22–89+)

60 (18–89+)

61 (20–89+)

61 (19–89+)

60 (18–89+)

60 (18–89+)

0.21

0.27

≥65 years old

35% (608)

38% (2761)

38% (1902)

38% (1518)

37% (9194)

38% (8349)

0.04

0.10

Sex M:F %

52:48

53:47

53:47

53:47

57:43

53:47

0.78

P < 0.001

Median TMB (range)

3.8 (0–90)

3.8 (0–219)

3.5 (0–373)

3.8 (0–608)

3.8 (0–865)

3.8 (0–608)

0.59

0.07

TMB ≥ 10 mutations/Mb (n)

4.7% (81)

6.6% (482)

3.2% (163)

9.5% (377)

11% (2670)

6.8% (1510)

0.002

P < 0.001

MSI-H % (n)

0.65% (11/1691)

3.4% (237/7048)

0.57% (28/4870)

5.6% (217/3860)

7.5% (1784/23,929)

3.2% (690/21,347)

P < 0.001

P < 0.001

PD-L1 1–49%

15% (68/445)

17% (315/1832)

13% (173/1282)

16% (166/1022)

13% (836/6552)

16% (880/5595)

0.92

0.21

PD-L1 ≥ 50%

1.6% (7/445)

1.4% (26/1832)

0.47% (6/1282)

1.2% (12/1022)

2.0% (134/6552)

1.0% (58/5595)

0.50

0.72

Non-Sq NSCLC (N = 21,866 KRAS mutated cases)

 

KRAS G12C

KRAS G12D

KRAS G12V

KRAS G12A

KRAS WT

KRAS non-G12C

G12C vs non-G12C

G12C vs. WT

# cases

8790

3085

4197

1548

40,042

13,076

–

–

Median age (range)

67 (24–89+)

69 (23–89+)

68 (24–89+)

69 (30–89+)

67 (18–89+)

68 (23–89+)

P < 0.001

P < 0.001

≥65 years old

60% (5282)

64% (1986)

62% (2584)

65% (1000)

59% (23,651)

62% (8130)

0.003

0.08

Sex M:F %

40:60

44:56

42:58

42:58

49:51

43:57

P < 0.001

P < 0.001

Median TMB (range)

7.8 (0–104)

5.0 (0–164)

6.3 (0–937)

6.3 (0–68)

5.2 (0–1765)

6.3 (0–1255)

P < 0.001

P < 0.001

TMB ≥ 10 mutations/Mb (n)

40% (3546)

24% (754)

34% (1412)

31% (485)

32% (12,842)

33% (4260)

P < 0.001

P < 0.001

MSI-H % (n)

0.20% (17/8473)

0.30% (9/2974)

0.20% (8/4054)

0.13% (2/1491)

0.35% (136/38,548)

0.26% (33/12,605)

0.59

0.03

PD-L1 1–49%

28% (1067/3879)

29% (377/1285)

28% (506/1820)

29% (189/655)

30% (4937/16,351)

28% (1578/5633)

0.72

0.001

PD-L1 ≥ 50%

44% (1690/3879)

37% (477/1285)

39% (705/1820)

37% (244/655)

29% (4769/16,351)

38% (2147/5633)

P < 0.001

P < 0.001

PDAC (N = 17,817 KRAS mutated cases)

 

KRAS G12C

KRAS G12D

KRAS G12V

KRAS G12R

KRAS WT

KRAS non-G12C

G12C vs non-G12C

G12C vs. WT

# cases

300

7654

5542

2825

1536

17,517

–

–

Median age (range)

67 (37–87)

66 (21–89+)

66 (28–89+)

66 (29–89+)

64 (23–89+)

66 (21–89+)

0.42

P < 0.001

≥65 years old

59% (176)

56% (4253)

55% (3065)

59% (1668)

49% (757)

56% (9888)

0.64

0.02

Sex M:F %

59:41

53:47

52:48

49:51

59:41

52:48

0.06

0.95

Median TMB (range)

1.7 (0–21)

1.3 (0–344)

1.3 (0–166)

1.3 (0–211)

1.7 (0–6906)

1.3 (0–355)

0.001

0.55

TMB ≥ 10 mutations/Mb (n)

2.0% (6)

1.0% (78)

0.79% (44)

0.85% (24)

5.5% (85)

1.0% (177)

0.32

0.03

MSI-H % (n)

0.34% (1/292)

0.37% (28/7472)

0.20% (11/5387)

0.15% (4/2759)

1.5% (23/1487)

0.32% (55/17,065)

0.74

0.37

PD-L1 1%-49%

35% (29/84)

33% (706/2118)

30% (457/1528)

25% (187/755)

24% (98/410)

31% (1484/4821)

0.64

0.16

PD-L1 ≥50%

2.4% (2/84)

7.7% (164/2118)

4.6% (71/1528)

6.0% (45/755)

6.6% (27/410)

6.3% (302/4821)

0.35

0.37

Endometrial (N = 2504 KRAS mutated cases)

 

KRAS G12C

KRAS G12D

KRAS G12V

KRAS G12A

KRAS WT

KRAS non-G12C

G12C vs non-G12C

G12C vs. WT

# cases

175

771

657

291

11,639

2329

–

–

Median age (range)

64 (35–89+)

63 (27–89+)

63 (24–89+)

64 (33–89+)

66 (23–89+)

64 (24–89+)

0.95

0.01

≥65 years old

46% (81)

44% (340)

44% (286)

49% (144)

56% (6484)

46% (1082)

1.0

0.03

Sex M:F %

0.57:99

0:100

0:100

0:100

0:100

0:100

0.21

0.03

Median TMB (range)

3.8 (0–54)

3.8 (0–509)

2.6 (0–384)

3.8 (0–393)

2.6 (0–908)

3.8 (0–733)

0.95

0.01

TMB ≥ 10 mutations/Mb (n)

30% (52)

34% (264)

21% (141)

31% (89)

16% (1919)

33% (759)

0.78

P < 0.001

MSI-H % (n)

26% (43/166)

31% (225/718)

19% (120/621)

27% (72/270)

13% (1459)

29% (619)

0.80

P < 0.001

PD-L1 1–49%

39% (25/64)

26% (66/258)

24% (54/224)

38% (39/104)

28% (1135/4005)

30% (245/814)

0.32

0.09

PD-L1 ≥50%

4.7% (3/64)

1.2% (3/258)

1.3% (3/224)

2.9% (3/104)

1.8% (73/4005)

2.0% (16/814)

0.32

0.14

  1. Ordinal relationships were examined using the Mann–Whitney U test; categorical relationships were examined using Fisher’s exact with correction for multiple comparisons. PD-L1 expression was only available for a subset of cases.
  2. KRAS WT includes samples WT for KRAS mutations and amplifications.
Back to article page